Scroll To Top
Issue Features




The next major advance in simplification of treatment could be the approval of antiretrovirals in nanosuspension formulations that release drug molecules slowly, and thus may enable once-monthly'or even less frequent'injectable antiretroviral therapy. A Tibotec Therapeutics experimental nonnuke, rilpivirine (TMC278), is the compound furthest along in the development of this technology, according to research released at the 15th Conference on Retroviruses and Opportunistic Infections.

Advocate Channel - The Pride StoreOut / Advocate Magazine - Fellow Travelers & Jamie Lee Curtis

From our Sponsors

Most Popular

Latest Stories

HIV Plus Editors